We are live on ! Find out more
LIPO

Lipella Pharmaceuticals
LIPO

Delisted

LIPO was delisted on the 18th of June, 2025.

Back to rankings

3 hedge funds and large institutions have $41.4K invested in Lipella Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $39.7K → $41.4K (+$1.7K)

0.05% more ownership

Funds ownership: 1.06% → 1.11% (+0.05%)

40% less funds holding

Funds holding: 5 → 3 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$40.4K
2
MCM
MAI Capital Management
Ohio
+$379
3
Bank of America
Bank of America
North Carolina
+$3

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$16.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$11.8K
3
HF
HRT Financial
New York
-$8K
4
TRCT
Tower Research Capital (TRC)
New York
-$3.63K

LIPO Hedge Fund Activity: Q4 2024 in Review

3 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q4 2024, worth a combined $41.4K — up 4.3% from $39.7K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of LIPO and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $40.4K. The largest seller was Vanguard Group, exiting entirely with an estimated $16.3K sold.

  • 3 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q4 2024, down from 5 in Q3 2024.
  • Funds reported $41.4K of Lipella Pharmaceuticals stock for Q4 2024, up 4.3% quarter-over-quarter.
  • 2 funds opened new Lipella Pharmaceuticals positions in Q4 2024 and 4 closed out, a net change of -2 holders.
  • The largest Lipella Pharmaceuticals buyer in Q4 2024 was Virtu Financial, an estimated $40.4K added.
  • The largest Lipella Pharmaceuticals seller in Q4 2024 was Vanguard Group, an estimated $16.3K sold.

Based on aggregated 13F filings for Q4 2024.